Recent Company News

• 02:37 AM ET Sep 18, 2025
  

  Bayer announces new drug application for gadoquatrane accepted for review in China (€27.38, 0.00)

• 04:13 PM ET Sep 16, 2025
  

  Cytokinetics participates in late cycle meeting with FDA; continues to expect a differentiated label and risk mitigation profile for aficamten, if approved - 8-K ($49.76, 0.00)

• 11:45 AM ET Sep 08, 2025
  

  JAMA publishes article on Bayer's Phase 3 trial of Elinzanetant for treating VMS (€28.26, 0.00)

• 09:37 AM ET Sep 04, 2025
  

  FDA discloses paragraph IV patent certification for Bayer's Kerendia

• 01:59 PM ET Aug 31, 2025
  

  Cytokinetics presents, publishes new data on aficamten at EWSC Congress 2025 ($35.33, 0.00)

• 07:42 AM ET Aug 30, 2025
  

  BridgeBio Pharma presents data from ATTRibute-CM study of acoramidis at ESC Congress 2025 ($51.76, 0.00)

• 04:02 AM ET Aug 30, 2025
  

  Cytokinetics presents, publishes primary results from MAPLE-HCM; to host webcast 2-Sep ($35.33, 0.00)

• 03:50 AM ET Aug 30, 2025
  

  Phase III VICTOR trial of Bayer's Verquvo fails to meet primary endpoint (€28.06, 0.00)

• 11:10 AM ET Aug 29, 2025
  

  Trump administration not expected to place new restrictions or ban on glyphosate -- Handelsblatt, citing US agricultural industry sources (€28.00, +0.07)

• 08:17 AM ET Aug 28, 2025
  

  StreetAccount Themes Headlines (28-Aug)